[go: up one dir, main page]

KR20010015817A - 항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체 - Google Patents

항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체 Download PDF

Info

Publication number
KR20010015817A
KR20010015817A KR1020007005263A KR20007005263A KR20010015817A KR 20010015817 A KR20010015817 A KR 20010015817A KR 1020007005263 A KR1020007005263 A KR 1020007005263A KR 20007005263 A KR20007005263 A KR 20007005263A KR 20010015817 A KR20010015817 A KR 20010015817A
Authority
KR
South Korea
Prior art keywords
receptor
antigen
virus
immunoglobulin molecule
glycoprotein
Prior art date
Application number
KR1020007005263A
Other languages
English (en)
Korean (ko)
Inventor
로날드엠. 버치
Original Assignee
유로-셀티큐 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로-셀티큐 에스.에이. filed Critical 유로-셀티큐 에스.에이.
Publication of KR20010015817A publication Critical patent/KR20010015817A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020007005263A 1997-11-14 1998-11-13 항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체 KR20010015817A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US8140398P 1998-04-10 1998-04-10
US60/065,716 1998-04-10
US60/081,403 1998-04-10
PCT/US1998/024303 WO1999025379A1 (en) 1997-11-14 1998-11-13 Modified antibodies with enhanced ability to elicit an anti-idiotype response

Publications (1)

Publication Number Publication Date
KR20010015817A true KR20010015817A (ko) 2001-02-26

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020007005263A KR20010015817A (ko) 1997-11-14 1998-11-13 항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체
KR1020007005264A KR20010015818A (ko) 1997-11-14 1998-11-13 합성된 가변성 부분 및 변형 특이성을 가지는면역글로불린 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020007005264A KR20010015818A (ko) 1997-11-14 1998-11-13 합성된 가변성 부분 및 변형 특이성을 가지는면역글로불린 분자

Country Status (9)

Country Link
EP (2) EP1032420A4 (zh)
JP (2) JP2001526021A (zh)
KR (2) KR20010015817A (zh)
CN (2) CN1294517A (zh)
AU (2) AU763029B2 (zh)
BR (2) BR9815289A (zh)
CA (2) CA2309990A1 (zh)
IL (2) IL136114A0 (zh)
WO (2) WO1999025379A1 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01004778A (es) * 1998-11-13 2003-07-21 Euro Celtique Sa Vacunas contraceptivas de anticuerpos.
PT1092779E (pt) * 1999-10-11 2010-01-19 Pasteur Institut Vectores lentivíricos para a preparação de composições imunoterapêuticas
WO2001088159A2 (en) * 2000-05-16 2001-11-22 Euro-Celtique S.A. Cd28 synthebody for the modulation of immune responses
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2380367T3 (es) 2000-12-05 2012-05-11 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
WO2002078613A2 (en) * 2001-04-02 2002-10-10 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
WO2003063768A2 (en) * 2001-10-25 2003-08-07 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
ATE554787T1 (de) * 2002-04-09 2012-05-15 Univ Missouri Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern
WO2003100008A2 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
NZ538996A (en) 2002-10-31 2008-04-30 Genentech Inc Methods and compositions for increasing antibody production
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
JP4452839B2 (ja) * 2004-03-09 2010-04-21 国立大学法人京都大学 Ｃｘｃｒ３阻害剤を含有する医薬組成物
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
SI2292663T1 (sl) * 2006-08-28 2014-02-28 Kyowa Hakko Kirin Co., Ltd Antagonistična humana monoklonska protitelesa, specifična za humani LIGHT
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
CN101970500B (zh) * 2008-03-12 2013-08-14 伊姆克罗尼责任有限公司 抗tyrp1抗体
JP5925116B2 (ja) * 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体
CN102816240B (zh) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 一种融合蛋白及其融合蛋白表达载体
EP2714083A4 (en) * 2011-05-27 2015-03-04 Fox Chase Cancer Ct RATIONAL-DESIGNED TYPE II RECEPTOR ANTIBODIES WITH A MULLERIAN-INHIBITABLE SUBSTANCE
MY188083A (en) * 2011-11-23 2021-11-16 In3Bio Ltd Recombinant proteins and their therapeutic uses
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
WO2014183649A1 (zh) * 2013-05-14 2014-11-20 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
CN103275914B (zh) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 展示保护性抗原的细菌菌蜕及其应用
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
WO2015177098A2 (en) * 2014-05-19 2015-11-26 Helsingin Yliopisto Modified adenoviruses for cancer vaccines development
CN105693859B (zh) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 抗人g2a单克隆抗体以及检测人巨噬细胞g2a表达量的试剂盒
CN111978382B (zh) * 2020-09-03 2022-03-04 吉林大学第一医院 一种球形孢子丝菌Gp70重组蛋白的制备方法及其应用
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
WO1990009804A1 (en) * 1989-02-24 1990-09-07 The Regents Of The University Of California Genetically engineered immunoglobulins
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DE69332930T2 (de) * 1992-11-16 2004-02-26 Cancer Research Fund Of Contra Costa, Walnut Creek Peptide mit breiter neoplastischer spezifizität
WO1994014847A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
WO1994014848A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Also Published As

Publication number Publication date
KR20010015818A (ko) 2001-02-26
EP1032420A4 (en) 2004-09-15
BR9815580A (pt) 2002-01-29
IL136113A0 (en) 2001-05-20
AU1459899A (en) 1999-06-07
WO1999025378A1 (en) 1999-05-27
AU2003252902A1 (en) 2003-11-06
EP1030684A1 (en) 2000-08-30
AU737457B2 (en) 2001-08-23
IL136114A0 (en) 2001-05-20
WO1999025378A9 (en) 1999-08-12
EP1030684A4 (en) 2004-09-15
CA2310269A1 (en) 1999-05-27
JP2002507544A (ja) 2002-03-12
AU763029B2 (en) 2003-07-10
EP1032420A1 (en) 2000-09-06
WO1999025379A1 (en) 1999-05-27
CN1327388A (zh) 2001-12-19
CA2309990A1 (en) 1999-05-27
CN1294517A (zh) 2001-05-09
AU1459799A (en) 1999-06-07
BR9815289A (pt) 2001-12-26
JP2001526021A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
KR20010015817A (ko) 항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체
TWI823906B (zh) 抗-cd73 抗體及其使用方法
TWI832035B (zh) 結合ccr8之抗體及融合蛋白及其用途
ES2427964T3 (es) Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
ES2349781T3 (es) Composiciones polipeptídicas que se enlazan con el cd20.
CN104080804B (zh) 去免疫化的血清结合结构域及其延长血清半衰期的用途
JP2017518958A (ja) 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
KR20080099290A (ko) 암 치료용 ｉｌ-17 길항 항체
JP2935520B2 (ja) ガン治療に用いられる新規高親和性改変抗体系統群
WO2008043146A9 (en) Antibodies against non functional p2x7 receptor
TW202003581A (zh) 對cd3具特異性之抗體及其用途
JP2022553908A (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
KR20040101428A (ko) 항유전인자형 항-ｃｅａ 항체 분자 및 암백신으로서의이의 용도
TWI862564B (zh) 癌治療用醫藥
WO2005021595A1 (en) Methods of antibody engineering using antibody display rules
CN115960240A (zh) 一种同时靶向人bcma和人cd3的双特异性抗体
AU737457C (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response
US20250066498A1 (en) Anti-glyco-lamp1 antibodies and their uses
MXPA00004581A (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response
AU9340701A (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response
JP2010514434A (ja) ヒトｌｄｌ受容体に対するモノクローナル抗体
WO2023091608A2 (en) Methods for treating anti-cancer drug-related skin rashes using benralizumab
US20190276517A1 (en) Methods and Compositions for Treating Melanoma
WO2000029443A1 (en) Contraceptive antibody vaccines
MXPA00004582A (en) Immunoglobulin molecules having a synthetic variable region and modified specificity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000515

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid